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Abstract Alpha-synuclein (ASN) is a presynaptic protein
that can easily change its conformation under different types
of stress. It’s assumed that ASN plays an important role in the
pathogenesis of Parkinson’s and Alzheimer’s disease.
However, the molecular mechanism of ASN toxicity has not
been elucidated. This study focused on the role of extracellular
ASN (eASN) in regulation of transcription of sirtuins (Sirts)
and DNA-bound poly(ADP-ribose) polymerases (PARPs) -
proteins crucial for cells’ survival/death. Our results indicate
that eASN enhanced the free radicals level, decreased mito-
chondria membrane potential, cells viability and activated
cells’ death. Concomitantly eASN activated expression of an-
tioxidative proteins (Sod2, Gpx4, Gadd45b) and DNA-bound
Parp2 and Parp3.Moreover, eASN upregulated expression of
Sirt3 and Sirt5, but downregulated of Sirt1, which plays an
important role in cell metabolism including Aβ precursor pro-
tein (APP) processing. eASN downregulated gene expression
of APP alpha secretase (Adam10) and metalloproteinases
Mmp2, Mmp10 but upregulatedMmp11.Additionally, expres-
sion and activity of pro-survival sphingosine kinase 1
(Sphk1), Akt kinase and anti-apoptotic protein Bcl2 were
inhibited. Moreover, higher expression of pro-apoptotic pro-
tein Bax and enhancement of apoptotic cells’ death were ob-
served. Summarizing, eASN significantly modulates tran-
scription of Sirts and enzymes involved in APP/Aβ metabo-
lism and through these mechanisms eASN toxicity may be
enhanced. The inhibition of Sphk1 and Akt by eASN may
lead to disturbances of survival pathways. These results sug-
gest that eASN through alteration of transcription and by in-
hibition of pro-survival kinases may play important pathogen-
ic role in neurodegenerative disorders.
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DMEM Dulbecco's Modified Eagle Medium
E45K α-synuclein mutated protein
eASN extracellular acting ASN
ETC electron transport protein complexes
EDTA ethylenediaminetetraacetic acid




anti-apoptotic protein growth arrest






HSP heat shock protein
LB Lewy body
MMP 2, 10, 11
(gene name
Mmp2, 10, 11)








NAD nicotinamide adenine dinucleotide
PAR poly(ADP-ribose)
PARP 1, 2, 3 poly(ADP-ribose) polymerase
1, 2, 3
PBS phosphate buffer saline
PC12 pheochromocytoma cell line
PD Parkinson’s disease
p-FTY720 FTY720 Phosphate, 2-amino-2[2-
(4-octylphenyl)ethyl]-1,3-propanediol,
mono dihydrogen phosphate ester
PGC1α Peroxisome proliferator-activated









ROS reactive oxygen species
S1P sphingosine-1-phosphate
SDS-PAGE sodium dodecyl sulfate polyacrylamide
gel electrophoresis
SEW2871 S1P1 receptor agonist
SIRT 1, 2, 3, 4, 5
(gene name
Sirt1, 2, 3, 4, 5)




Sphk1 sphingosine kinase 1
Introduction
Alpha-synuclein (ASN) is a 140-amino acid soluble protein
that is abundantly expressed in the nervous system, where it
constitutes 1% of total cytosolic proteins [1–3]. In physiolog-
ical conditions, ASN occurs in presynaptic terminals in close
proximity to synaptic vesicles. ASN is involved in the regu-
lation of synaptic vesicle transport and in the formation of
synaptic connections, their structure and plasticity [4–7].
The data of Bartels et al. 2011 [8] indicate that ASN occurs
physiologically as a helically folded tetramer that is resistant
to aggregation. The tetramer can dissolve into unfoldedmono-
mers which subsequently can aggregate into soluble
protofibrils and insoluble β-amyloid fibres [9]. Recent data
have indicated that alterations in ASN expression and confor-
mation could play an important role in familial (A30P, A53T
mutations) and in sporadic forms of Parkinson’s disease (PD)
as well as in the pathology of about 60% of Alzheimer’s dis-
ease’s (AD) cases [10–13]. Misfolding of this protein leads to
aggregation/ fibrilisation of ASN, which in β-sheet structure
is toxic to cells [14–16]. The aggregates of ASN are the main
components of intracellular inclusions called Lewy bodies
(LBs), which are the pathological hallmarks of PD, AD-
forms with LBs and other synucleinopathies [17–21]. The
latest studies including our data demonstrate that ASN could
be secreted from neuronal cells and nerve endings into the
extracellular space [12, 22, 23]. Extracellular alpha-
synuclein (eASN) can alter ionic homeostasis and synaptic
transmission in neuronal cells [24, 25]. Several recent studies
support the hypothesis that, just as the human prion protein,
ASN can transfer protein alteration from cell to cell [26, 27].
Recently, ASN was detected in rodent and human brain inter-
stitial fluid, which confirms that it is secreted outside the cell.
eASN affects neuronal and glial homeostasis, activates in-
flammatory reactions and promotes neuronal death [12,
28–32]. Moreover, eASN induces amyloid-beta (Aβ) secre-
tion and enhances the level of the amyloid-beta precursor pro-
tein (APP), and in this way it potentiates its own and Aβ
toxicity [11, 23, 27, 33–36]. Themechanism of ASN secretion
is not well understood, however, oxidative stress seems to
have a promoting role in this process [12, 22, 29].
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Our last study indicated that ASN secretion is also
modulated by the pharmacological inhibition of sphingo-
sine kinase(s) (Sphk1/2) [22] and this effect is probably
mediated by free radical–dependent processes. These en-
zymes are responsible for the synthesis of sphingosine-1-
phosphate (S1P), a pleiotropic lipid mediator which exerts a
mitogenic, pro-survival but also pro-apoptotic effects
within the cell [37–40]. Sphk1/2 are key enzymes that
maintain homeostasis between S1P and ceramide, and
through this mechanism they may play an important role
in the regulation of cell survival and death. The inhibition
of Sphk1/2 alters S1P-dependent signalling, regulated also
by the PI3K/Akt pathway. The three from five receptors
(S1P1, S1P2 and S1P3) are specific for S1P transduce
information by PI3K/Akt. Our last data indicated the neu-
roprotective effect of S1P (1μM) in dopaminergic cells-
exposed to different types of stress [41–43]. The lower
S1P concentration has been described in AD [40, 44], in
the dopaminergic SH-SY5Y cell PD model and also in the
animal PD model evoked by 1-methyl-4-phenylpyridinium
MPP+/MPTP, respectively [22, 41, 45]. The alteration of
S1P level in AD correlated well with reduced expression/
activity of Sphk1/2 and with the ratio of dementia.
Another important role in regulation of cell viability is
played by nicotinamide adenine dinucleotide (NAD) depen-
dent enzymes such as sirtuins (SIRTs) and DNA-bound
poly(ADP-ribose) polymerases (PARPs). The enzyme fami-
lies of SIRTs and PARPS are engaged in the regulation of
energy metabolism, anti-oxidative processes, DNA repair
and cell survival [46–49]. In mammalian cells, there are seven
members of the sirtuins family (SIRTs 1-7), among which
SIRT1 has been the most investigated. Recently, it was found
that SIRT1 protects cells against ASN and protein Tau aggre-
gation. The lifespan of mouse is increased by overexpressing
SIRT1 and decreased by knocking out SIRT1 in brain
[50–52]. SIRT1 activates alpha-secretase gene expression
(Adam10) and supresses amyloid beta (Aβ) production [53].
Alpha-secretase activates APP processing inside the Aβ se-
quence and in this way prevents formation of neurotoxic Aβ.
Degradation of APP by alpha-secretase leads to release of
soluble, neuroprotective terminal domain of APP. Several me-
talloproteinases as ADAM10, ADAM17, ADAM9 express
alpha-secretase activity [54]. Moreover, SIRT1 activates per-
oxisome proliferator-activated receptor (PPAR)γ coactivator
1α (PGC1α) and through this mechanism it increases
mitochondrial biogenesis [47]. Among mitochondrial
located SIRTs, SIRT3 was the best investigated and it was
demonstrated that this enzyme is responsible for the regu-
lation of electron transport protein complexes (ETC) and
for expression and activity of several anti-oxidative pro-
teins, e.g. superoxide dismutase (SOD2) and glutathione
peroxidase (GPx), which are crucial in the molecular
mechanism of cell viability [46]. The roles of other
mitochondrial SIRTs , SIRT4 and SIRT 5 is not fully under-
stood. Outeiro et al. [55] found that inhibition of cytosolic
SIRT2 protects against ASN toxicity in vitro and in the
Drosophila model of PD. It was indicated that this
cytosolic-located SIRT2 exerted the opposite effect than
pro-survival SIRT1 [49]. The other NAD-regulated enzyme
family (17 members) of PARPs, as compared to SIRTs,
exhibits higher affinity to the βNAD+ particle [56, 57].
The most important enzyme of this family is DNA-bound
PARP1, which in the brain is responsible for more than 90%
of poly-ADP-ribosylation processes [58, 59]. Also PARP2
and PARP3 are DNA-bound enzymes, and all of them are
activated in stress and are involved in the DNA repair
mechanism under middle stress [60]. However, under mas-
sive DNA damage, PARP1 can be over-activated and
responsible for apoptotic or necrotic cell death [58, 61, 62].
In this study we investigated the role of eASN in the reg-
ulation of gene expression of SIRTs, PARPs and enzymes
involved in the APP/Aβ metabolism. Moreover, the expres-




The ASN protein was subjected to the aggregation/
oligomerisation procedure as described in Danzer et al. [33]
with some modifications. Lyophilised ASN (from rPeptide,
USA) was dissolved in 1 ml mixture of 50 mM sodium phos-
phate buffer, pH 7.0, containing 20% ethanol, to a final con-
centration of ASN 10 μM. After 4 h of shaking at room tem-
perature (RT) using a thermomixer 5436; Eppendorf,
Wesseling-Berzdorf, Germany), the ASN protein was
lyophilised again and resuspended in 0.5 ml mixture of
50 mM sodium phosphate buffer, pH 7.0, containing 10%
ethanol. Then it was mixed for 24 h with open lids to evapo-
rate the residual ethanol. Concentrations of obtained ASN
forms were determined using spectrophotometric measure-
ment (NanoDrop) with absorbance at 280/290 nm.
Verification of ASN Purity and Structure
The purity of the ASN protein was determined using mass
spectrometry/HPLC. Then aliquots containing 2 μg of the
ASN protein prepared after the procedure as described above
(Danzer et al. [33]) were analysed by SDS-PAGE followed by
silver staining. The analysis indicated that ASN before and
after the described procedure was in monomeric/oligomeric
form. Then the ASN pure protein before and after the
aggregation/oligomerisation procedure was analysed by circu-
lar dichroism (CD) on a JASCO J-815 CD spectropolarimeter
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in the range of ~270-195 nmwith a data pitch of 1.0 nm. ASN
before the procedure was in a random coil structure which was
no longer observed after the aggregation/oligomerisation pro-
cedure. This indicated that the structure of ASN changed into
the β-sheet structure. In addition, the conformation state of
ASN was confirmed using Thioflavin T (ThT, benzothiazole
dye) fluorescence.
Cell Culture and Cell Treatment Protocol
Rat pheochromocytoma (PC12) cells were cultured in
Dulbecco’s Modified Eagle’s Medium (DMEM) supplement-
ed with 10% heat-inactivated fetal bovine serum (FBS), 5%
heat inactivated horse serum, 2 mM L-glutamine, 50 U/ml
penicillin and 50 μg/ml streptomycin in a 5% CO2 atmo-
sphere at 37 °C. Cell treatment was performed in low-serum
(2% FBS) DMEM to stop proliferation. The PC12 cells were
used for experiments between five and ten passage numbers.
For the MTTassay, the PC12 cells were seeded onto collagen-
coated 96-well plates at a density of 7×104 cells per well in
100 μl of medium. For other analyses, the PC12 cells were
seeded at 3×105 cells/10-mm tissue culture dishes. Then the
PC12 cells were treated with eASN (0.5 μM for 24-48 h).
Control cells were treated with sodium phosphate buffer sub-
jected to the same oligomerisation procedure as the eASN.
Additionally, cells were treated with Z-DEVD-FMK (R&D
Systems), Cyclosporin A (Sigma-Aldrich, 30024),
SEW2871 (Cayman Chemical), p-FTY720 (Cayman
Chemical), AK-7 (Sigma-Aldrich, SML0152), PJ-34
(Sigma-Aldrich), Resveratrol (Sigma-Aldrich), Quercetin
(Sigma-Aldrich). Appropriate solvent was added to respective
controls.
Cytotoxicity Assays
Cell Viability Analysis (MTT Assay)
Mitochondrial function and cellular viability were evaluated
using 2-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT). After 48 h incubation with the appropriate
compounds, MTT (2.5 mg/ml) was added to all of the wells.
The cells were incubated at 37 °C for 2 h. Then the medium
was removed, the formazan crystals were dissolved in DMSO
and absorbance at 595 nm was measured.
Trypan Blue Staining
Trypan blue solution was added to the culture medium. The
cells were examined immediately under an optical micro-
scope. The number of blue stained cells and the total number
of cells were counted. If cells took up trypan blue, they were
considered nonviable.
Determination of Apoptosis Using Hoechst 33342
Fluorescent Staining
For morphological studies, PC12 cells were subjected for 24-
96 h to oxidative stress evoked by eASN (0,5μM). PC12 cells
were collected and washed in PBS. The cells were fixed in
MetOH for 30 min in 4 C. Nuclei were visualised with
Hoechst 33342 (0.2 μg/ml, Riedel-de-Haën Germany) fluo-
rescent staining. The cells were examined under a fluores-
cence microscope (Olympus BX51, Japan) and photographed
with a digital camera (Olympus DP70, Japan). Cells with typ-
ical apoptotic nuclear morphology (nuclear shrinkage, con-
densation) were identified and counted. The results were
expressed as apoptotic index according to the equation apo-
ptotic index=(apoptotic ratio/average apoptotic ratio for con-
trol) where apoptotic ratio=(apoptotic cells )/(all cells).
Mitochondrial membrane potential (ΔΨm) assay
Detection of mitochondrial membrane potential (ΔΨm)was per-
formed using the JC-1 detection kit (Thermo Fisher Scientific)
according to the manufacturer’s directions. JC-1 (5′,6,6′-
tetrachloro-1,1′,3,3′-tetraethylbenzimidazolylcarbocyanine io-
dide) is a cationic dye which accumulates in mitochondrial
membranes of healthy cells, resulting in red fluorescence
(590 nm), while in apoptotic and necrotic cells, which have
diminished mitochondrial membrane potential, JC-1 exists
in the green fluorescent (529 nm) monomer form. Images
are captured using a fluorescence image scanning unit
(FMBIO III) instrument (flow cytometer) and the ratios
of red (live cells) and green (dead cells) fluorescence were
calculated. All assays were performed in quadruples and
repeated twice.
Determination of Free Radicals Using
2’7’-dichlorofluorescein (DCF)
The level of reactive oxygen species (ROS) was deter-
mined using 2’,7’ dichlorodihydrofluorescein diacetate
(H2DCF-DA) exactly as described previously by Cieślik
et al. 2015 [63].
Determination of Sphk1 Activity
Sphingosine kinase activity assay was performed according to
the method of Don et al. 2007 [64], as described previously
[22, 41]. After 24 h incubation, the PC12 cells were washed
with iced PBS and lysed in 50 mM Hepes, pH 7.4, 15 mM
MgCl2, 10 mM KCl,10% glycerol, 2 mM ATP, 5 mM NaF,
1 mM deoxypyridoxine, and EDTA-free complete protease
inhibitor (Roche Applied Science). Lysates were cleared by
centrifugation at 15 000 g for 5 min. The 100 μg of lysates and
NBD-Sphingosine (10 μM final) (Avanti Polar Lipids) were
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mixed in reaction buffer, 50 mM Hepes, pH 7.4, 15 mM
MgCl2, 0.5% Triton X-100, 10% glycerol, 2 mM ATP and
incubated for 30 min at 30 °C. The reactions were stopped
by the addition of an equal amount of 1 M potassium phos-
phate (pH 8.5), followed by the addition of 2.5-fold
chloroform/methanol (2:1), and then centrifuged at 15 000 g
for 1 min. Only the reactant NBD-S1P, but not the substrate
NBD-sphingosine, was collected in the alkaline aqueous
phase. After the addit ion of an equal volume of
dimethylformamide, the fluorescence value was determined
(λex = 485 nm, λem = 538 nm).
Immunochemical Determination of Protein Level (Western
Blot)
The PC12 cells were washed three times with ice-cold PBS,
scraped from the culture dishes and suspended in 1xCell Lysis
Buffer (from Cell Signalling Technology). Protein levels were
determined using the Lowry method [65], and the proteins
were mixed with 5× Laemmli sample buffer and denatured
for 5 min at 95 °C. A total of 50 μg of the protein was loaded
per lane on 7.5%, 10% or 15% acrylamide gels and separated
by sodium dodecyl sulfate (SDS)-polyacrylamide gel electro-
phoresis. The proteins were transferred onto a nitrocellulose
membrane at 10V overnight at 4 °C. The quality of transfer
was verified with Ponceau S staining. The membranes were
incubated in 5% dry milk in TBS with Tween 20 (TBS-T) for
1 h at RT and exposed overnight at 4 °C to the following
antibodies: anti-Sphk1 (Cell Signalling Technology, 1:500),
anti-pAkt and anti-Akt (Cell Signalling Technology, at a dilu-
tion of 1:1000), anti-SIRT1 (Santa Cruz Biotechnology,
1:1000) and anti-Gapdh (Sigma-Aldrich, 1:50 000). After
treatment for 1 h with the corresponding horseradish
peroxidase-coupled secondary antibodies (anti-rabbit from
Amersham Biosciences or anti-mouse from GE Healthcare),
the protein bands were detected by chemiluminescent reaction
using ECL reagent (Amersham Biosciences). GAPDH was
detected on membranes as a loading control. Densitometric
analysis and size-marker-based verification were performed
using Total Lab 4 software. After detection, the membranes
were treated with stripping buffer (50 mM glycine, pH 2.5,
1% SDS) for further blots.
Determination of Gene Expression
The PC12 cells were washed twice with ice-cold PBS and
suspended in 1 ml of TRI reagent (Sigma-Aldrich). RNA
was isolated from the cell pellet according to the manufac-
turer’s protocol. Digestion of DNA contamination was per-
formed by using DNase I according to the manufacturer’s
protocol (Sigma-Aldrich). Reverse transcription was per-
formed using a High Capacity cDNA Reverse Transcription
Kit according to the manufacturer’s protocol (Applied
Biosystems, Foster City, CA, USA). The level of mRNA for
selected genes was analysed using TaqMan Gene Expression
Assays (Applied Biosystems, Foster City, CA, USA) accord-
ing to the manufacturer’s instructions: Bax: Rn01480161_g1,
Bcl2: Rn99999125_m1, Bcl2l1: Rn00437783_m1, Adam10:
Rn01530753_m1, Bace1: Rn00569988_m1, Psen1:
Rn00569763_m1, Psen2: Rn00579412_m1, Sod1:
Rn00566938_m1, Sod2 : Rn00690588_g1, Cyb5b :
Rn00577982_m1, Gadd45b: Rn01452530_g1, Gpx4:
Rn00820818_g1, Sir t1: Rn01428096_m1 , S ir t2:
Rn01457502_m1 , S i r t3 :Rn01501410_m1, Sir t4 :
Rn01481485_m1, Sirt5 :Rn01450559_m1, Parp1 :
Rn00565018_m1, Parp2: Rn01414610_m1, Parp3:
Rn01447502_m1, Mmp2: Rn01538170_m1, Mmp9:
Rn00579162_m1, Mmp10: Rn00591678_m1, Mmp11:
Rn01428817_m1, Actb: 4352340E. Actb was selected and
used in all of the studies as a reference gene. Quantitative
PCR was performed on an ABI PRISM 7500 apparatus. The
relative levels of mRNA were calculated using the ΔΔCt
method.
Statistical Analysis
The results were expressed as mean values ± SEM.
Differences between the means were analysed using a
Student’s t-test for two groups or one-way analysis of variance
ANOVAwith the Newman–Keuls post hoc test among multi-
ple groups, p values < 0.05 were considered significant. The
statistical analyses were performed using Graph Pad Prism
version 5.0 (Graph Pad Software, San Diego, CA, USA).
Results
In the present research, we studied the molecular mechanism
of eASN evoked cytotoxicity leading to a cells’ death. The
study was focused on the role of eASN in regulation of gene
expression of sirtuins, DNA-bound PARPs and other stress
response proteins engaged in regulation of cell survival/death.
The MSS/HPLC analysis of ASN used in this study indicated
its purity (Fig. 1a). It was found that ASN which was used for
the experiments, adopted the monomeric/oligomeric forms
(Fig. 1b). Using circular dichroism (CD) it was observed that
ASN was in random coil structure (Fig. 1c), which changed
during the aggregation/oligomerization procedure into the β-
sheet structure - confirmed by thioflavin T fluorescence deter-
mination (Fig. 1d).
This study demonstrated that exogenous, extracellularly
applied eASN in monomeric/oligomeric form significantly
enhanced the free radicals level in a concentration-dependent
manner (Fig. 2a) and concomitantly reduced PC12 cells’ via-
bility (Fig. 2b). About 50% of cells show low viability at
0.5 μM of eASN and this concentration was further used.
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For analysing the effect of eASN on cells’ viability, the mito-
chondrial membrane potential (MMP) using JC-1 staining
was evaluated. eASN significantly decreased MMP by about
20% comparing to the control cells (without eASN) (Fig. 2c).
Experiments with trypan blue staining demonstrated a signif-
icant increase in number of dead cells under the eASN toxicity
conditions (Fig. 2d).
The eASN evoked stress may lead to activation of
cytoprotective processes to counteract free radicals mediated
damages of macromolecules. We determined the transcription
level of selected enzymes involved in antioxidative defence
against eASN toxicity. eASN significantly increased the
mRNA level of the mitochondrial anti-oxidative enzymes:
superoxide dismutase 2 (Sod 2), glutathione peroxidase 4
(Gpx4) as well as Gadd45b (anti-apoptotic protein growth
arrest and the DNA-damage-inducible beta) (Fig. 3a). There
was no significant effect of eASN on Sod1 and cytochrome b5
(Cyb5b) gene expression (Fig. 3a). Moreover, DNA-bound
PARPs expression was determined under eASN evoked oxida-
tive stress. Gene expression of Parp1 was not altered by eASN,
but Parp2 and Parp3 were significantly upregulated (Fig. 3b).
The protein level of the mitochondrial apoptosis-inducing factor
(AIF) regulated by PARP/PARwas not changed as compared to
the control conditions (data not shown). The recent studies
demonstrated the significant role of other NAD dependent
enzymes sirtuins (SIRTs) in the regulation of anti-oxidative
defence in cells. Our results showed that mRNA level of Sirt3
and Sirt5 (mitochondria located enzymes) was significantly
Fig. 1. Determination of eASN purity and structure. eASN used for
aggregation /oligomerisation procedure (A/O) was subjected to MMS/
HPLC analysis of its purity in 50 mM sodium phosphate buffer, pH 7.0
before and after the A/O procedure (a). Then the electrophoretic analysis
of the eASN aggregation forms was performed. 2 μg of protein before
and after the A/O procedure was subjected to non-denaturing
electrophoresis followed by silver staining (b). The presence of eASN
monomers, dimers and trimers was reported. In the next step eASNbefore
and after the A/O procedure was subjected to analysis of circular
dichroism spectra of eASN in 50 mM sodium phosphate buffer, pH 7.0
(c). Note the significant differences in spectra before and after eASN
oligomerisation procedure. Finally, analysis of Thioflavin T(ThT)
fluorescence before and after eASN oligomerisation was done (d)
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enhanced, but expression of Sirt1 was significantly decreased
and Sirt2, 4 were not altered (Fig. 3c).
Our previous study indicated close relationship betweenASN
and APP levels. Moreover, it was found that ASN enhanced Aβ
peptides secretion and its toxicity leading to irreversible
alterations in cells viability [11]. In this study the effect of
eASN on expression of enzymes engaged in APP metabolism
and in degradation of Aβ peptides was investigated. Our results
demonstrated significant downregulation of gene expression of
α-secretase (Adam10), the key enzyme in non-amyloidogenic
Fig. 3. The effect of eASN on
gene expression of anti-oxidative
enzymes and DNA-bound
PARPs. The mRNA level of
Sod1, Sod2, Gpx4, Gadd45b,
Cyb5b (a), Parp1,2,3 (b),
Sirt1,2,3,4,5 (c) after 24 h of
0,5 μM eASN treatment was
measured with real-time PCR.
The value expresses the fold of
the above gene stimulation
normalized against Actb (β-
actin). Data represent the mean
value ±S.E.M of four separate




(phosphate buffer -treated PC12
cells) by Student’s t-test.
Fig. 2. The effect of eASN on
ROS generation, PC12 cells’
viability, mitochondrial
membrane potential and cells’
death. PC12 cells were treated
with 0,125–2 μM eASN for 48 h.
ROS generation was determined
using DCF probe (a), cell
viability by MTT assay (b),
mitochondrial membrane
potential determined by JC-1
staining (c), cells’ death by
Trypan Blue staining (d). Data
represent the mean value ± S.E.M
of four-six independent
experiments with four to six
replications. *p<0.05, **p<0.01
and ***p<0.001 versus control
(phosphate buffer - treated PC12
cells) by one-way ANOVA
followed by the Newman–Keuls
post-hoc test.
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APP processing (Fig. 4a). eASN had no effect on gene expres-
sion of β-secretase (Bace1) and also did not affect γ-secretase
crucial subunits, presenilin 1 and presenilin 2 (Psen1,2) (Fig. 4a).
However, eASN decreased gene expression of Mmp2 and
Mmp10 and upregulated gene expression ofMmp11 (Fig. 4b).
Other crucial enzymes involved in regulation of cell survival
and death are sphingosine kinase (SphK1) and PI3K/Akt kinase.
It was found that eASN induced a significant decrease in the
activity and protein level of Sphk1 (Fig. 5a, b). Similar effects as
eASN were exhibited by ASN-mutated forms, i.e. A30P, E46K
and A53T on PC12 cells’ viability and the Sphk1 activity
(Fig. S1a, b). It was observed that eASN also decreased the
pro-survival pathway regulated by Akt kinase. The protein level
of total Akt was not altered (Fig. 6a), but significantly lower
phosphorylation of Akt kinase on serine 473 was observed,
which may be responsible for its lower activity (Fig. 6b). In
consequence, the ratio of phospho-Akt to total Akt was signifi-
cantly lower after ASN treatment as compared to the control
value (Fig. 6c). It was previously shown that Akt inhibits cells’
death by preventing the release of cytochrome c from
mitochondria and by regulation of pro and anti-apoptotic Bcl-2
proteins. Our study indicated that eASN enhanced expression of
the pro-apoptotic Bcl-2 protein, Bax, and downregulated the
anti-apoptotic protein Bcl2 (Fig. 7a). Moreover, eASN activated
apoptotic cells’ death was visualised by nuclei staining (Hoechst
33342) (Fig. 7b). Representative pictures showed enhanced
number of cells with typical apoptotic morphological changes
in cell nuclei characterized by nuclear shrinkage, chromatin
condensation and nuclear fragmentation (Fig. 7c).
Furthermore, we also analysed several compounds as S1P
analogues (SEW2871, p-FTY720), the caspase inhibitor (Z-
DEVD-FMK) and an inhibitor of the inner mitochondria
membrane permeability (Cyclosporin A) in order to evaluate
their potentially protective effect against eASN. As a result no
effect of those compounds on cells’ viability was observed.
Moreover, neither Resveratrol nor quercetin, specific SIRT2
inhibitor (AK-7) nor inhibitor of PARP-1 (PJ-34) were able to
rescue cells against eASN toxicity (Fig. S2).
All described molecular alterations evoked by eASN were
demonstrated on Fig. 8.
Fig. 4. Effect of eASN on gene expression of selected Aβ secretases and
metalloproteinases. The mRNA level of Adam10, Bace1, Psen1, Psen2
(a) and Mmp2,9,10,11 (b) after 24 h of 0,5 μM eASN treatment was
measured with real-time PCR. The value expresses the fold of the
above gene stimulation normalized against Actb (β-actin). Data
represent the mean value ± S.E.M of four-six separate experiments with
four replications. The relative level of mRNA was calculated by ΔΔCt
method. **p<0.01 and ***p<0.001 versus control(phosphate buffer -
treated PC12 cells) by Student’s t-test
Fig. 5. Sphk1 activity, gene expression/protein level in eASN-treated
PC12 cells. PC12 cells were treated with 0,5 μM eASN for 24 h.
Fluorescence value of Sphk1 activity was measured. Data represent the
mean value ± S.E.M of five independent experiments (a). Sphk1 (~45
kDa) immunoreactivity in the cells’ homogenate was measured. A
representative Western blot from one typical experiment is shown
below the graph. Data represent the mean value ± S.E.M of four
independent experiments normalized against GAPDH (~37 kDa) (b).
*p<0.05 and **p<0.01 versus control (phosphate buffer-treated PC12
cells) by Student’s t-test.
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Discussion
Our results showed that eASNmay play an important role as a
potent regulator of transcription. It differently affects gene
expression of SIRT1 and mitochondrial SIRT3 and SIRT5. It
was found that eASN decreased mRNA level of SIRT1.
Moreover, eASN downregulated the expression of Adam10,
the enzyme responsible for non-amyloidogenic APP metabo-
lism. The inhibition of Adam10 by ASN may disturb the bal-
ance between the non-amyloidogenic and amyloidogenic
pathways of APP processing. Previous studies showed that
SIRT1 deletion decreased lifespan and enhanced ASN aggre-
gates in brain of PD mouse experimental model [50, 51]. The
upregulation of SIRT1 leads to suppression of Aβ production
by activation of alpha-secretase [51, 53]. eASN may translo-
cate from extracellular compartment inside the cell and it can
influence gene expression directly or by interaction with dif-
ferent transcription factors, however this process is not fully
understood [66]. Additionally, it was previously found that
ASN significantly upregulated the APP protein level and Aβ
secretion [11, 23]. All the above-mentioned data together in-
dicate the important relationship between ASN/APP/Aβ and
suggest that ASN/Aβ interaction can lead to irreversible mo-
lecular alterations and to cell death [11]. eASN by inhibition
of Adam10 and by downregulation of gene expression of
Mmp2, Mmp10 with concomitant activation of Mmp11 may
alter APP/Aβ processing and may lead to higher Aβ produc-
tion. It was demonstrated that MMP2 and MMP9 may be
involved in the Aβ catabolism, as they can degrade Aβ fibrils
in vitro as well as amyloid plaques in brain slices from APP/
PS1 mice. MMPs were found in the brains of AD patients
[67–69] and the results indicated that they participated in
Aβ clearance by its degradation. Wan et al. (2015) demon-
strated that Aβ-42 oligomers induced leakage of the blood-
brain barrier (BBB) and that MMPs may play an important
role in this process [70]. Our data demonstrated that ASN
significantly decreased the transcription of Mmp2 and
Mmp10 which may be responsible for the lower Aβ catabo-
lism leading, in consequence, to a higher Aβ concentration.
Moreover, it is possible to suggest that the upregulation of
Mmp11may enhance APP degradation. It was previously pro-
posed that MMP12 exacerbated the cascade of proteolytic
processes by subsequent activation of several MMPs [71].
The involvement of ASN in the APP/Aβ metabolism by
downregulation of Adam10, Mmp2 and Mmp10 expression
may have a significant impact on the cells’ fate.
Moreover, ASN through the inhibition of pro-survival ki-
nases Sphk1 and Akt could profoundly affect cells’ viability.
Our results showed that both native and mutated eASN simi-
larly decreased the activity of Sphk1. Recently, we also dem-
onstrated that Sphk1 inhibition stimulated ASN secretion, the
release of cytochrome c from the mitochondria, activated pro-
apoptotic protein expression and led to caspase-dependent do-
paminergic cells’ death in stress induced by MPP+ [22, 41].
Our studies suggested that Sphk1 inhibition by activation of
oxidative stress led to ASN release into the extracellular com-
partment [22]. Previous data demonstrated the role of
oxidative/nitrosative stress in ASN release from the brain
Fig. 6. Akt kinase phosphorylation/activity under eASN toxicity. PC12
cells were treated with 0,5 μM eASN for 24 h. Effect of 0,5 μM eASN on
the level of immunoreactivity of Akt (pan) (a), pAkt (pSer473, ~60 kDa)
(b) and pAkt/Akt (pan) ratio (c) in the cells’ homogenate. A
representative Western blot from one typical experiment is shown
below the graph. Data represent the mean value ± S.E.M of four
independent experiments normalized against GAPDH (~37 kDa) (a,b).
**p<0.01 versus control (phosphate buffer -treated PC12 cells) by
Student’s t-test.
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synaptosomal fraction [29]. Moreover, it was found that
eASN induced Aβ release and that prolonged action of ASN
(10 μM for 48 h) led to cell death [11, 72]. In the present work
the eASN- evoked Sphk1 decline could also be explained on
the basis of the action of reactive oxygen species (ROS).
Oxidative stress can regulate Sphk1 expression and activity
depending on cell’s type and intensity of stress [73]. It was
reported that ROS overproduction, induced by Aβ peptides
and MPP+, may decrease Sphk1 activity in SH-SY5Y cells
[41, 74, 75]. eASN via Sphk(s) inhibition disturbs the
sphingolipid homeostasis, which may lead to lower S1P syn-
thesis, and concomitantly to lower pro-survival signaling
through S1P-specific receptors. A growing number of studies
have emphasized the important role of bioactive sphingolipids
such as S1P and ceramide in the regulation of neuronal cell
survival and death, respectively. The sphingolipid equilibrium
between S1P and ceramide (also called the sphingolipid rheo-
stat) may be crucial for cell survival [38, 43, 73, 76]. Several
studies have indicated that an increased ceramide concentra-
tion suppressed the viability of dopaminergic neuronal cells
[43, 77, 78]. It was also shown that disturbances in the S1P
level and signaling could be responsible for the
pathomechanism of AD and other neurodegenerative diseases
[79, 80]. We hypothesized that lower S1P synthesis may be
also important in the mechanism of cell death evoked by
eASN. Sphk(s) pharmacological inhibition has a similar effect
as MPP+ on dopaminergic cell viability [22]. Another very
important pro-survival pathway inhibited by eASN is Akt,
which is also involved in S1P receptor-mediated signaling. It
was demonstrated previously that ASN has a dual effects on
Fig. 8. Schematic representation of eASN evoked alteration of gene
expression and molecular changes leading to decrease of cells’ viability
and to activation of cells’ death.
Fig. 7. The effect of eASN on Bcl-2 pro-apoptotic and anti-apoptotic
proteins gene expression and on apoptotic cells’ death. The mRNA level
of Bax, Bcl2 and Bcl2-L1 after 24 h of 0,5 μM eASN treatment was
measured with real-time PCR (a). The value expresses the fold of the
above gene stimulation normalized against Actb (β-actin). Microscopic
examination of cell nuclei, stained with DNA-binding fluorochrome
Hoechst 33342. The cells were treated with 0,5 μM eASN, 24h. Cells
with typical apoptotic nuclear morphology (nuclear shrinkage, chromatin
condensation) were identified and counted. The results were expressed as
percentages of apoptotic cells in the whole cells’ population from one
exemplary experiment in four to eight replications (b,c). Data represent
the mean value ± S.E.M of four – eight separate experiments with two
replications. The relative level of mRNA was calculated by ΔΔCt
method. **p<0.01 versus control(phosphate buffer -treated PC12 cells)
by Student’s t-test
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Akt phosphorylation/activity depending on its structure and
concentration [81–83]. In our study eASN significantly re-
duced Akt phosphorylation/activity which, in consequence,
may decrease cells’ viability.
There is a strong evidence that ASN overexpression
enhances the ROS level [12, 84, 85]. Our previous data
showed that eASN enhanced the calcium influx by
voltage-dependent calcium channels and disturbed mito-
chondrial function, which in consequence induced oxida-
tive stress, altered CdK5 and GSK-3β and activated
caspase-dependent programmed cell death [11, 86–88].
The production of ROS, which is well established to oc-
cur during abnormal protein conformation, e.g. ASN or
Aβ peptide oligomerization, could be a common funda-
mental mechanism in neurodegenerative disorders such as
AD and PD [12, 58, 76, 89, 90]. ASN itself or its frag-
ment(s) directly or through the interaction with different
transcription factors can influence gene expression for
several important enzymes as SIRT1, α-secretase and oth-
er proteins as Bax/Bcl2. Concomitantly eASN leads to
significantly higher expression of Sod2, which is one of
the most important anti-oxidative enzymes responsible for
dismutat ion of superoxide in the mitochondria .
Additionally, higher expression of the Gpx4 and
Gadd45b were found.
Moreover, eASN up-regulates Sirt3 and Sirt5 expression,
which may have anti-apoptotic properties [46, 91]. The data
suggest that SIRT3 may be mainly engaged in the activation
of an antioxidative mechanism against ASN toxicity. SIRT1
and SIRT3 play a significant role in the regulation of redox
potential, energy and metabolic status of the cell. SIRT1 and
SIRT3 deacetylate SOD1 and SOD2, respectively. SIRT1 ex-
erts the effect through the regulation of α-secretase, heat
shock protein (HSP) [50, 51, 92] and PGC1-α, which results
in enhanced mitochondria biogenesis [47]. However, the low-
er expression of SIRT1 observed in this study may lead to
disruption of the SIRT1–PGC1-α relationships. This alter-
ation has been suggested as being of significance for DNA
repair impairment and may play an important role in the
pathomechanism of neurodegenerative diseases. The role of
SIRT5 is not till now fully elucidated. This enzyme is also
responsible for protein desuccinylation and demalonylation,
and for cytochrome c release from mitochondria.
Lower Sirt1 expression may affect several cellular process-
es, including PARP1 function. It was reported that SIRT1 has
been able to mitigate rapid PARP1 activation in oxidative
stress by deacetylated PARP1 reversing its enzymatic stimu-
lation and reducing it activity to nearly undetectable levels.
Moreover, SIRT1 has been shown to interact with the DNA-
binding domain and, to a lesser extent, with the
automodification domain of PARP1 [93]. It was also reported
that PARP2 may regulate the activity of the SIRT1 [94] and
SIRT1 promotor. We showed that eASN upregulated gene
expression for the DNA-bound enzyme PARP2 and PARP3.
The previous studies demonstrated the significance of PARP1
in neurodegenerative disorders [95]. There are evidences in-
dicating the role of DNA-bound PARP(s) in regulation of
transcription factors, DNA repair and SIRT(s). The relation-
ship between PARP(s) and SIRT(s) may have a significant
impact on cells’ fate in pathological conditions, including neu-
rodegenerative disorders. These two families of enzymes were
previously suggested to compete for the same substrate
βNAD+. However, recently published data have demonstrat-
ed that, opposite to PARP1, the affinity of PARP2 and prob-
ably PARP3 to NAD is similar as in the case of SIRT1, and
that many functions of PARP2 are independent from NAD
[93, 94]. Our data indicate that eASN may serve as important
modulator of transcription and may exert its toxicity through
alterations of gene expression of enzymes involved in APP/
AB metabolism and through inhibition of Sphk1 and Akt
mediated signaling. All these data suggest that eASN may
have a significant impact on the progression of neurodegener-
ative disorders.
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